References
- Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133–vi137.
- National Comprehensive Cancer Network (NCCN). Guidelines for patients: multiple myeloma. Version 1. 2016. Available at: https://www.nccn.org/patients/guidelines/myeloma/files/assets/common/downloads/files/myeloma.pdf [cited 2017 Apr 24].
- Voorhees PM, Orlowski RZ, Mulkey F, et al. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015;171:373–377.
- Nishihori T, Baz R, Shain K, et al. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015;95:426–435.
- Lazaryan A, Hussein MA, Reu FJ, et al. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol. 2014;89:349–354.
- Ning YM, He K, Dagher R, et al. Anthracyclines survive targeted therapy. Continued progress in treatment options for multiple myeloma: from past to present and future. Oncology. 2007;21:1503–1508. discussion 1511, 1513, 1516 passim.
- Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. 2010: London (UK): European Medicines Agency; 2010. (no. CPMP/EWP/QWP/1401/98 Rev. 1/Corr **).
- Committee for Human Medicinal Products (CHMP). Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product. 2013: London (UK): European Medicines Agency; 2013. (no. EMA/CHMP/806058/2009/Rev. 02).